238 related articles for article (PubMed ID: 18405468)
1. Payment to healthcare professionals for patient recruitment to trials: systematic review and qualitative study.
Raftery J; Bryant J; Powell J; Kerr C; Hawker S
Health Technol Assess; 2008 Apr; 12(10):1-128, iii. PubMed ID: 18405468
[TBL] [Abstract][Full Text] [Related]
2. Paying clinicians to join clinical trials: a review of guidelines and interview study of trialists.
Raftery J; Kerr C; Hawker S; Powell J
Trials; 2009 Mar; 10():15. PubMed ID: 19272166
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Pharmaceutical Company Payments and Conflict of Interest Disclosures Among Oncology Clinical Practice Guideline Authors in Japan.
Saito H; Ozaki A; Sawano T; Shimada Y; Tanimoto T
JAMA Netw Open; 2019 Apr; 2(4):e192834. PubMed ID: 31026027
[TBL] [Abstract][Full Text] [Related]
6. Tip of the Iceberg? Country- and Company-Level Analysis of Drug Company Payments for Research and Development in Europe.
Ozieranski P; Martinon L; Jachiet PA; Mulinari S
Int J Health Policy Manag; 2022 Dec; 11(12):2842-2859. PubMed ID: 35297231
[TBL] [Abstract][Full Text] [Related]
7. A cross-sectional study of all clinicians' conflict of interest disclosures to NHS hospital employers in England 2015-2016.
Feldman HR; DeVito NJ; Mendel J; Carroll DE; Goldacre B
BMJ Open; 2018 Mar; 8(3):e019952. PubMed ID: 29581205
[TBL] [Abstract][Full Text] [Related]
8. Pharmaceutical industry payments to NHS trusts in England: A four-year analysis of the Disclosure UK database.
Ozieranski P; Saghy E; Mulinari S
PLoS One; 2023; 18(11):e0290022. PubMed ID: 37910526
[TBL] [Abstract][Full Text] [Related]
9. International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency.
Ozieranski P; Saito H; Rickard E; Mulinari S; Ozaki A
Global Health; 2023 Mar; 19(1):14. PubMed ID: 36869318
[TBL] [Abstract][Full Text] [Related]
10. The effect of financial incentives on the quality of health care provided by primary care physicians.
Scott A; Sivey P; Ait Ouakrim D; Willenberg L; Naccarella L; Furler J; Young D
Cochrane Database Syst Rev; 2011 Sep; (9):CD008451. PubMed ID: 21901722
[TBL] [Abstract][Full Text] [Related]
11. Guidelines, editors, pharma and the biological paradigm shift.
Singh AR; Singh SA
Mens Sana Monogr; 2007 Jan; 5(1):27-30. PubMed ID: 22058616
[TBL] [Abstract][Full Text] [Related]
12. Involving South Asian patients in clinical trials.
Hussain-Gambles M; Leese B; Atkin K; Brown J; Mason S; Tovey P
Health Technol Assess; 2004 Oct; 8(42):iii, 1-109. PubMed ID: 15488164
[TBL] [Abstract][Full Text] [Related]
13. Disclosure of payments by pharmaceutical companies to healthcare professionals in the UK: analysis of the Association of the British Pharmaceutical Industry's Disclosure UK database, 2015 and 2016 cohorts.
Mulinari S; Ozieranski P
BMJ Open; 2018 Oct; 8(10):e023094. PubMed ID: 30344175
[TBL] [Abstract][Full Text] [Related]
14. Overview and transparency of non-research payments to healthcare organizations and healthcare professionals from pharmaceutical companies in Japan: Analysis of payment data in 2016.
Ozaki A; Saito H; Senoo Y; Sawano T; Shimada Y; Kobashi Y; Yamamoto K; Suzuki Y; Tanimoto T
Health Policy; 2020 Jul; 124(7):727-735. PubMed ID: 32439213
[TBL] [Abstract][Full Text] [Related]
15. The impact of the National Institute for Health Research Health Technology Assessment programme, 2003-13: a multimethod evaluation.
Guthrie S; Bienkowska-Gibbs T; Manville C; Pollitt A; Kirtley A; Wooding S
Health Technol Assess; 2015 Aug; 19(67):1-291. PubMed ID: 26307643
[TBL] [Abstract][Full Text] [Related]
16. Drug company payments to General Practices in England: Cross-sectional and social network analysis.
Saghy E; Mulinari S; Ozieranski P
PLoS One; 2021; 16(12):e0261077. PubMed ID: 34874975
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the transparency of pharmaceutical company disclosure of payments to patient organisations in the UK.
Rickard E; Ozieranski P; Mulinari S
Health Policy; 2019 Dec; 123(12):1244-1250. PubMed ID: 31455562
[TBL] [Abstract][Full Text] [Related]
18. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Pharmaceutical Industry Payments to UK Health Care Organizations in 2015.
Ozieranski P; Csanadi M; Rickard E; Tchilingirian J; Mulinari S
JAMA Netw Open; 2019 Jun; 2(6):e196253. PubMed ID: 31225896
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
